Overall, the trials investigating kidney endpoints indicated that SGLT2-Is reduced the incidence of renal outcomes to more than 40% in patients with T2DM with or without prevalent CVD. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.